Last reviewed · How we verify
MN-166
At a glance
| Generic name | MN-166 |
|---|---|
| Also known as | ibudilast, Pinatos® capsule, Pinatos capsule |
| Sponsor | MediciNova |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Scalable Expanded Access With Analysis of Neurofilament and Other Biomarkers for Ibudilast in ALS
- Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS (PHASE2, PHASE3)
- RECLAIM: Recovering From COVID-19 Lingering Symptoms Adaptive Integrative Medicine (PHASE2, PHASE3)
- Pilot Study of the Effect of Ibudilast on Neuroinflammation in Methamphetamine Users (PHASE2)
- Study to Evaluate Ibudilast and TMZ Combo Treatment in Newly Diagnosed and Recurrent Glioblastoma (PHASE1, PHASE2)
- Ibudilast for Treating Alcohol Use Disorder (PHASE2)
- Ibudilast for the Treatment of Alcohol Use Disorder (PHASE2)
- Efficacy, Safety, Tolerability, and Biomarkers of Ibudilast (MN-166) in Patients Hospitalized With COVID-19 at Risk for ARDS (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MN-166 CI brief — competitive landscape report
- MN-166 updates RSS · CI watch RSS
- MediciNova portfolio CI